rambuza 60mg tvrdá tobolka s prodlouženým uvolňováním
zentiva, k.s., praha array - 5493 urapidil - tvrdá tobolka s prodlouženým uvolňováním - 60mg - urapidil
litalir 500mg tvrdá tobolka
cheplapharm arzneimittel gmbh, greifswald array - 1991 hydroxykarbamid - tvrdá tobolka - 500mg - hydroxykarbamid
temozolomide glenmark 100mg tvrdá tobolka
glenmark pharmaceuticals s.r.o., praha array - 10609 temozolomid - tvrdá tobolka - 100mg - temozolomid
temozolomide glenmark 140mg tvrdá tobolka
glenmark pharmaceuticals s.r.o., praha array - 10609 temozolomid - tvrdá tobolka - 140mg - temozolomid
temozolomide glenmark 180mg tvrdá tobolka
glenmark pharmaceuticals s.r.o., praha array - 10609 temozolomid - tvrdá tobolka - 180mg - temozolomid
temozolomide glenmark 20mg tvrdá tobolka
glenmark pharmaceuticals s.r.o., praha array - 10609 temozolomid - tvrdá tobolka - 20mg - temozolomid
temozolomide glenmark 250mg tvrdá tobolka
glenmark pharmaceuticals s.r.o., praha array - 10609 temozolomid - tvrdá tobolka - 250mg - temozolomid
entocort 3mg tvrdá tobolka s řízeným uvolňováním
tillotts pharma gmbh, rheinfelden array - 5362 budesonid - tvrdá tobolka s řízeným uvolňováním - 3mg - budesonid
cyclo 3 fort 150mg/150mg/100mg tvrdá tobolka
pierre fabre medicament, lavaur array - 13453 suchÝ listnatcovÝ extrakt; 709 hesperidin-methylchalkon; 102 kyselina askorbovÁ - tvrdá tobolka - 150mg/150mg/100mg - rutosid, kombinace
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.